Scandion Oncology A/S
Stockholm Stock ExchangeTotal Valuation
Scandion Oncology A/S carries a market capitalization of 962,520.00, placing it among publicly traded companies globally. Its enterprise value stands at -2.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 962,520.00 |
| Enterprise Value | -2.36M |
Share Statistics
Scandion Oncology A/S currently has 234.76M shares outstanding.
| Shares Outstanding | 234.76M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.05 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | -0.37 |
| P/OCF Ratio | -0.37 |
Financial Position
Scandion Oncology A/S maintains a current ratio of 1.81, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.80, indicating moderate leverage, while an interest coverage ratio of -74.54 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.81 |
| Quick Ratio | 1.27 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | -74.54 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -138.75 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -4.25M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Scandion Oncology A/S's stock has declined approximately -97.4375% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.4375% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.05 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -41.15M, while operating income came in at -41.15M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -41.15M |
| Pretax Income | -40.91M |
| Net Income | -36.66M |
| EBITDA | -41.15M |
| EBIT | -41.15M |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
Scandion Oncology A/S holds 12.69M in cash and equivalents against 66,000.00 in total debt, resulting in a net debt position of -12.68M. Total book value stands at -224.28M, with working capital of 8.13M providing operational flexibility.
| Cash & Cash Equivalents | 12.69M |
| Total Debt | 66,000.00 |
| Net Debt | -12.68M |
| Equity (Book Value) | -224.28M |
| Book Value Per Share | -1.06 |
| Working Capital | 8.13M |
Cash Flow
Scandion Oncology A/S produced -27.61M in operating cash flow over the past twelve months.
| Operating Cash Flow | -27.61M |
| Capital Expenditures | N/A |
| Free Cash Flow | -27.61M |
| FCF Per Share | -0.13 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -131.76 |
| FCF Yield | -269.26 |
Stock Splits
Scandion Oncology A/S's most recent stock split took place on May 31, 2024 with a 250:447 split ratio.
| Last Split Date | 5/31/2024 |
| Split Ratio | 250:447 |
Scores
Scandion Oncology A/S posts an Altman Z-Score of -24.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.78 |